InspireMD Announced Its Support For Centers For Medicare & Medicaid Services Final National Coverage Determination Which Expands Coverage Of Carotid Artery Stenting And Transcarotid Artery Revascularization To Include Asymptomatic & Standard Risk Patients
Portfolio Pulse from Benzinga Newsdesk
InspireMD has announced its support for the Centers for Medicare & Medicaid Services' final National Coverage Determination, which expands coverage of carotid artery stenting and transcarotid artery revascularization to include asymptomatic and standard risk patients.
October 12, 2023 | 11:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InspireMD's support for the expanded coverage could potentially increase the demand for its products, as more patients will now be eligible for the procedures.
The expanded coverage by CMS means that more patients will now be eligible for carotid artery stenting and transcarotid artery revascularization procedures. As InspireMD is a provider of these services, this could potentially increase the demand for its products, positively impacting its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100